GMDA

Gamida Cell Ltd. [GMDA] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

GMDA Stock Summary

Top 10 Correlated ETFs

GMDA


Top 10 Correlated Stocks

GMDA


In the News

08:00 10 Dec 2023 GMDA

Gamida Cell to Present Corporate Highlights at the Piper Sandler 35th Annual Healthcare Conference

BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that its management team will present corporate highlights at the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, NY.

08:53 10 Dec 2023 GMDA

These Israeli pharmaceutical stocks are down in the wake of Hamas attack

Shares of Israeli pharmaceutical companies took a hit in premarket trades Monday after Hamas' attack on Israel.

07:02 10 Dec 2023 GMDA

Gamida Cell: The Treacherous Path To Profitability

Gamida Cell's approved therapy, Omisirge, shows faster neutrophil recovery and reduced infections in blood cancer patients compared to standard care. The long-term study of Omisirge includes a diverse patient population, improving its marketability. Cash headwinds continue to be a challenge, and their latest financial filings do not ease this uncertainty.

10:57 10 Dec 2023 GMDA

Gamida Cell (GMDA)'s Technical Outlook is Bright After Key Golden Cross

Gamida Cell Ltd. (GMDA) is looking like an interesting pick from a technical perspective, as the company reached a key level of support.

04:30 10 Dec 2023 GMDA

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that Michele Korfin, Chief Operating and Chief Commercial Officer, will present corporate highlights at the upcoming Jefferies Healthcare Conference on June 8, 2023 at 9:30 a.m. ET. Ms. Korfin's presentation will include an overview of the company's corporate strategy and commercial strategy for Omisirge®. The webcast will be available on the “Invest.

08:39 10 Dec 2023 GMDA

Gamida Cell Ltd. (GMDA) Q1 2023 Earnings Call Transcript

Gamida Cell Ltd. (NASDAQ:GMDA ) Q1 2023 Results Conference Call May 15, 2023 4:30 PM ET Company Participants Mike Kuczkowski - Corporate Communications Abbey Jenkins - President and CEO Michele Korfin - COO and Chief Commercial Officer Ronit Simantov - Chief Medical Officer and Scientific Officer Shai Lankry - CFO Conference Call Participants Edward Tenthoff - Piper Sandler Gil Blum - Needham & Company Vernon Bernardino - H.C.

05:20 10 Dec 2023 GMDA

Gamida Cell Announces the Date of Its First Quarter 2023 Financial Results and Webcast

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today announced that the company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to review its first quarter 2023 financial results and provide an update on the company. To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conferenc.

12:47 10 Dec 2023 GMDA

Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today

Penny stocks with unusual options activity today The post Penny Stocks To Buy Now? 3 To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

09:01 10 Dec 2023 GMDA

Why Is Gamida Cell (GMDA) Stock Down 19% Today?

Gamida Cell (NASDAQ: GMDA ) stock is falling on Wednesday after the cell therapy company revealed details of a public securities offering. According to a press release from the company, it is selling both shares of GMDA stock, as well as warrants to purchase shares of its stock.

01:10 10 Dec 2023 GMDA

Gamida Cell Stock Jumps Over 100% on FDA Approval

Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.

GMDA Financial details

Company Rating
Buy
Market Cap
42.44M
Income
-98.89M
Revenue
673K
Book val./share
0
Cash/share
0.4
Dividend
-
Dividend %
-
Employees
143
Optionable
No
Shortable
Yes
Earnings
14 Nov 2023
P/E
-0.49
Forward P/E
-0.76
PEG
0.28
P/S
63.07
P/B
127.25
P/C
0.8
P/FCF
-0.51
Quick Ratio
2.96
Current Ratio
3.32
Debt / Equity
223.08
LT Debt / Equity
219.16
-
-
EPS (TTM)
-1.29
EPS next Y
-0.42
EPS next Q
-0.11
EPS this Y
55.13%
EPS next Y
-67.44%
EPS next 5Y
-101.55%
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-96.77%
-
-
-
-
SMA20
-54.29%
SMA50
-66.32%
SMA100
-79.35%
Inst Own
28.68%
Inst Trans
0.92%
ROA
-84%
ROE
812%
ROC
0.75%
Gross Margin
7%
Oper. Margin
10847%
Profit Margin
-14695%
Payout
-
Shs Outstand
132.64M
Shs Float
112.81M
-
-
-
-
Target Price
7
52W Range
0.22-2.51
52W High
-
52W Low
-
RSI
29.5
Rel Volume
0.71
Avg Volume
1.88M
Volume
1.34M
Perf Week
1.04%
Perf Month
-58.44%
Perf Quarter
-83.51%
Perf Half Y
-85.32%
-
-
-
-
Beta
1.253
-
-
Volatility
0.01%, 0.19%
Prev Close
-1.84%
Price
0.32
Change
2.3%

GMDA Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-10.53-1.17-1.75-1.56-2.42
Operating cash flow per share
-5.26-1.29-1.11-1.38-1.1
Free cash flow per share
-5.59-1.39-1.38-1.63-1.2
Cash per share
12.081.882.911.621.01
Book value per share
4.911.192.260.74-0.13
Tangible book value per share
4.911.192.260.74-0.13
Share holders equity per share
4.911.192.260.74-0.13
Interest debt per share
4.030.320.421.391.7
Market cap
49.95M126.68M366.86M150.49M82.34M
Enterprise value
9.68M90.81M247.6M174.31M121.64M
P/E ratio
-0.94-3.69-4.8-1.63-0.53
Price to sales ratio
00000
POCF ratio
-1.89-3.34-7.54-1.84-1.17
PFCF ratio
-1.78-3.09-6.07-1.55-1.07
P/B Ratio
2.023.623.723.43-10.26
PTB ratio
2.023.623.723.43-10.26
EV to sales
00000
Enterprise value over EBITDA
-0.3-3.14-4.15-2.01-1.63
EV to operating cash flow
-0.37-2.39-5.09-2.13-1.73
EV to free cash flow
-0.34-2.22-4.1-1.8-1.58
Earnings yield
-1.06-0.27-0.21-0.61-1.87
Free cash flow yield
-0.56-0.32-0.16-0.64-0.93
Debt to equity
00.170.081.81-12.96
Debt to assets
00.090.050.540.83
Net debt to EBITDA
1.241.242-0.27-0.53
Current ratio
9.284.986.033.882.68
Interest coverage
-1.66-14.51-5.86-33.1917.11
Income quality
0.51.10.670.910.89
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
0.060.080.240.180.09
Capex to revenue
00000
Capex to depreciation
-6.12-1.43-4.92-34.93-14.44
Stock based compensation to revenue
00000
Graham number
34.125.589.425.12.62
ROIC
-1.36-1.03-0.57-0.681.41
Return on tangible assets
-0.81-0.5-0.49-0.62-1.24
Graham Net
4.020.731.61-0.15-1.07
Working capital
55.49M45.31M108.43M73.18M41.67M
Tangible asset value
24.69M34.98M98.74M43.94M-8.02M
Net current asset value
21.71M22.91M73.24M-6.24M-66.25M
Invested capital
00.170.081.81-12.96
Average receivables
00000
Average payables
2.19M1.57M3.75M7.3M7.33M
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-2.14-0.98-0.77-2.119.24
Capex per share
-0.33-0.1-0.27-0.25-0.1

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-09-302022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-0.31-0.68-0.29-0.31-0.01
Operating cash flow per share
-0.24-0.25-0.29-0.22-0.12
Free cash flow per share
-0.26-0.31-0.3-0.22-0.12
Cash per share
1.011.010.610.530.4
Book value per share
0.22-0.13-0.2-0.250
Tangible book value per share
0.22-0.13-0.2-0.250
Share holders equity per share
0.22-0.13-0.2-0.250
Interest debt per share
1.31.661.261.010.56
Market cap
96.1M82.34M62.18M197.21M156.46M
Enterprise value
119.08M121.64M111.12M233.89M181.24M
P/E ratio
-1.3-0.47-0.7-1.56-25.75
Price to sales ratio
0000232.48
POCF ratio
-6.56-5.09-2.79-8.96-8.43
PFCF ratio
-6.01-4.19-2.69-8.97-8.42
P/B Ratio
7.09-10.26-4.05-7.67409.57
PTB ratio
7.09-10.26-4.05-7.67409.57
EV to sales
0000269.31
Enterprise value over EBITDA
-7.05-5.93-5.71-12.51-10.52
EV to operating cash flow
-8.13-7.52-4.99-10.63-9.76
EV to free cash flow
-7.45-6.19-4.81-10.63-9.75
Earnings yield
-0.19-0.53-0.36-0.16-0.01
Free cash flow yield
-0.17-0.24-0.37-0.11-0.12
Debt to equity
5.76-12.96-6.23-3.53223.08
Debt to assets
0.680.830.910.810.72
Net debt to EBITDA
-1.36-1.92-2.51-1.96-1.44
Current ratio
2.762.682.162.843.32
Interest coverage
-23.0257.96-14.19-1.460
Income quality
0.820.711.060.6912.23
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
000020.56
Research and developement to revenue
00006.31
Intangibles to total assets
00000
Capex to operating cash flow
0.090.220.0400
Capex to revenue
0000-0.02
Capex to depreciation
-7.93-71.2-7.80.06-0.01
Stock based compensation to revenue
00002.04
Graham number
1.241.391.141.320.02
ROIC
-0.182.38-0.24-0.27-0.2
Return on tangible assets
-0.16-0.35-0.21-0.28-0.01
Graham Net
-0.65-1.07-0.96-0.81-0.36
Working capital
39.99M41.67M25.89M38.13M47.86M
Tangible asset value
13.56M-8.02M-15.37M-25.71M382K
Net current asset value
-38.05M-66.25M-72.33M-79.36M-48.86M
Invested capital
5.76-12.96-6.23-3.53223.08
Average receivables
00069K407K
Average payables
2.33M4.15M5.39M3.42M2.05M
Average inventory
0001.2M2.36M
Days sales outstanding
000090.4
Days payables outstanding
10.11000239.23
Days of inventory on hand
0000334.12
Receivables turnover
00001
Payables turnover
8.90000.38
Inventory turnover
00000.27
ROE
-1.375.41.451.23-3.98
Capex per share
-0.02-0.05-0.0100

GMDA Frequently Asked Questions

What is Gamida Cell Ltd. stock symbol ?

Gamida Cell Ltd. is a IL stock and trading under the symbol GMDA

What is Gamida Cell Ltd. stock quote today ?

Gamida Cell Ltd. stock price is $0.32 today.

Is Gamida Cell Ltd. stock public?

Yes, Gamida Cell Ltd. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap